

TANZANIA - MEASLES SECOND DOSE VACCINE SUPPORT This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Tanzania

2. Grant Number: 1415-TZA-09a-X / 14-TZA-08d-Y

3. Date of Decision Letter: 4 July 2014

4. Date of the Partnership Framework Agreement: 1 July 2013

5. Programme Title: NVS, Measles second dose Routine

6. Vaccine type: Measles, Measles Rubella
The country is approved for measles second dose support; the country started with
measles vaccine and the decision letter is revised according to the country's request to
switch to measles-rubella vaccine

- **7.** Requested product presentation and formulation of vaccine: Measles, 10 dose(s) per vial, LYOPHILISED, Measles Rubella, 10 dose(s) per vial, LYOPHILISED
- **8. Programme Duration**¹: 2014 2015
- **9.** Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):

	2014	2015	Total ²
Programme	US\$875,000	US\$831,000	US\$1,706,000
Budget (US\$)			

10. Vaccine Introduction Grant: Already disbursed in January 2014.

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.



11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³

Type of supplies to be purchased with GAVI funds in	2014
each year	
Number of Measles vaccines doses	2,419,400
Number of AD syringes	2,133,100
Number of re-constitution syringes	266,200
Number of safety boxes	26,400
Annual Amounts (US\$)	US\$875,000
Total amount for 2014 has already been disbursed to UNICEF for procurement of vaccines and devices	

- 12. Procurement agency: UNICEF.
- 13. Self-procurement: Not applicable.
- **14.** Co-financing obligations: Not applicable.
- 15. Operational support for campaigns: Not applicable

	2014
Grant amount (US\$)	US\$

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat

17. Financial Clarifications: Not applicable.

18. Other conditions:

Country has presented an official request to GAVI and UNICEF SD to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the Rubella component as from September 2014. As such, country will make the required payments to UNICEF SD as indicated in the table below.

³ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.



	2014	2015
Number of doses of vaccines for Measles Second Dose	1,209,4004	2,125,517
approved by GAVI.		
Amount for vaccines approved by GAVI in US\$ (excluding	\$326,538	\$637,655
freight and insurance).		
Number of doses of Measles-Rubella vaccine that can be	593,705	1,099,405
purchased with GAVI support.		
Number of doses of Measles-Rubella vaccine to be funded by	615,695	1,026,112
country.		
Amount for Measles-Rubella vaccines to be funded by	\$338,632	\$595,145
country (excluding freight and insurance).		
		C .1

Country understands that vaccines will be purchased only after receipt of full payment of the respective amounts due from Country and GAVI to the procurement agency for the number of doses as indicated in this Decision Letter. In the event that country wishes to revert to measles vaccine, country should inform UNICEF and GAVI <u>immediately</u> in order to agree on an appropriate arrangement.

Signed by,

On behalf of the GAVI Alliance

Hind Khatib-Othman

Managing Director, Country Programmes

a Books (OIC)

4 July 2014

⁴ Out of the total volume approved of 2,419,400 doses for 2014, only the remaining volume not yet shipped of 1,209,400 doses could be replaced by the MR vaccine.

